DS 1501Alternative Names: Anti-siglec-15-antibody-Daiichi-Sankyo; DS1501
Latest Information Update: 11 Feb 2015
At a glance
- Originator Daiichi Sankyo Company
- Class Antibodies; Osteoporosis therapies
- Mechanism of Action Immunomodulators; Siglec-15 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Osteoporosis
Most Recent Events
- 31 Jan 2015 Phase-I clinical trials in Osteoporosis in USA (unspecified route)